Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline begins trial of DMD drug

GlaxoSmithKline begins trial of DMD drug

21st January 2011

GlaxoSmithKline has commenced a new clinical study of GSK2402968, an investigational treatment for Duchenne muscular dystrophy (DMD).

In association with Prosensa, the company has administered the first patient with therapy as part of the phase III trial, which will compare the efficacy of the drug to placebo among ambulant boys.

Subjects have been selected for the study based on whether they have dystrophin gene mutations amenable to an exon 51 skip, with the primary endpoint of the research being an improvement in muscle function after 48 weeks.

This represents the most advanced study currently being conducted for DMD, a rare and debilitating neuromuscular condition.

Dr Philippe Monteyne, head of development and chief medical officer for GlaxoSmithKline's rare disease division, said: "There is no approved treatment to alter the course of DMD, a disease that puts boys in wheelchairs and often leads to death in early adulthood."

This comes in the same week that GlaxoSmithKline announced the commencement of another phase III study, which will focus on a promising new influenza therapy option.ADNFCR-8000103-ID-800356565-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.